Orchestra BioMed Holdings, Inc.(OBIO)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Orchestra BioMed Holdings, Inc. (OBIO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores OBIO at 32.0/100 on a 32-signal composite quality model, placing it at rank #2,441 of 2,961 stocks — the bottom half of the AI-ranked universe. OBIO scores in the top quartile across revenue growth (99.3), institutional flow (82.5). Areas of concern include balance sheet strength (1.9) and free cash flow (4.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Orchestra BioMed Holdings, Inc. reports quarterly revenue of $88.0K, net income of $-23.8M, free cash flow of $-19.6M. Top institutional holders of OBIO by reported 13-F value include RTW INVESTMENTS, PERCEPTIVE ADVISORS, BlackRock, based on the most recent SEC filings. OBIO trades on the Nasdaq exchange and files with the SEC under CIK 1814114. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Orchestra BioMed Holdings, Inc. directly from SEC EDGAR.